Nexien Biopharma, Inc. financial data

Symbol
NXEN on OTC
Location
4340 E Kentucky Ave, Suite 206, Glendale, CO
State of incorporation
DE
Fiscal year end
June 30
Former names
Intiva BioPharma Inc. (to 9/12/2018), Kinder Holding Corp. (to 11/6/2017)
Latest financial report
10-Q - Q3 2024 - Nov 18, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.83 % -89.3%
Debt-to-equity -102 % +15.5%
Return On Equity 56.4 % -59.8%
Return On Assets -3.02K % -342%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 70.8M shares
Common Stock, Shares, Outstanding 70.5M shares +8.8%
Entity Public Float 687K USD -56.9%
Common Stock, Value, Issued 7.05K USD +8.8%
Weighted Average Number of Shares Outstanding, Basic 70.5M shares +9.13%
Weighted Average Number of Shares Outstanding, Diluted 70.5M shares +9.13%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 0 USD
General and Administrative Expense 78.7K USD -66.4%
Net Income (Loss) Attributable to Parent -196K USD +42.6%
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.95K USD -72.6%
Assets, Current 4.95K USD -77.5%
Assets 4.95K USD -77.5%
Liabilities, Current 397K USD +26.8%
Liabilities 397K USD +26.8%
Retained Earnings (Accumulated Deficit) -11.6M USD -1.73%
Stockholders' Equity Attributable to Parent -392K USD -34.7%
Liabilities and Equity 4.95K USD -77.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -9.23K USD +46%
Net Cash Provided by (Used in) Financing Activities 10K USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 70.5M shares +8.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 770 USD
Deferred Tax Assets, Valuation Allowance 726K USD +5.41%
Deferred Tax Assets, Operating Loss Carryforwards 726K USD +5.41%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 11.2M USD +1.18%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%